Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02784834 · ClinicalTrials.gov registry record · Phase 1
Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL
A Phase 1 study, sponsored by Michael Choi.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT02784834 is a Phase 1 study that was terminated before completion, run by Michael Choi. The registered enrollment target is 2 participants.
The verdict
NCT02784834, a Phase 1 study, was terminated before completion, sponsored by Michael Choi.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of the study is to investigate the safety of the investigational drug called dimethylfumarate (DMF). DMF is a type of drug called an immunomodulatory drug. This drug is approved by the United States (U.S.) Food and Drug Administration (FDA) as a treatment for patient with multiple sclerosis. Although there is evidence from tests on laboratory animals that DMF can decrease the number of CLL cells, we do not know if this will work in humans with CLL. This drug will be given to humans with CLL for the first time in this study. Therefore, the goal of this study is to see if DMF is safe and tolerable in study participants. Participants will be evaluated to find out what effects (good and bad) DMF has on the body and see how long the drug stays in the body.
Interventions
- DRUG dimethyl fumarate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2016-06 |
| Est. Completion | 2019-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02784834
The ClinicalTrials.gov registry entry for NCT02784834 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Michael Choi, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which dimethyl fumarate is the first listed.
NCT02784834 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02784834 about?
NCT02784834 is a clinical study titled "Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL". The purpose of the study is to investigate the safety of the investigational drug called dimethylfumarate (DMF). DMF is a type of drug called an immunomodulatory drug. This drug is approved by the United States (U.S.) Food and Drug Administration (FDA) as a treatment for patient with multiple sclero...
What is the current status of trial NCT02784834?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2016-06. Estimated completion is 2019-02.
What interventions are being tested in trial NCT02784834?
The interventions under investigation include: dimethyl fumarate (DRUG).
Who is sponsoring clinical trial NCT02784834?
This trial is sponsored by Michael Choi, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.